Ron Scarboro, Azurity Pharmaceuticals, explains how cross-functional development, disciplined reformulation, and post-approval metrics can help proven medicines work in everyday use.
News|Articles|June 29, 2014
PTSM: Pharmaceutical Technology Sourcing and Management
- PTSM: Pharmaceutical Technology Sourcing and Management-07-02-2014
- Volume 10
- Issue 7
Cytovance Biologics Manufactures AM0010 for ARMO BioSciences
Author(s)Pharmaceutical Technology Editors
Cytovance Biologics completes GMP manufacture of ARMO BioSciences& lead product.
Advertisement
Cytovance Biologics, a contract manufacturer of mammalian and microbial biologics, has announced the successful completion of GMP manufacture of ARMO BioSciences’ lead product, AM0010, a PEGylated form of recombinant human interleukin-10 (PEG-IL-10).
ARMO BioSciences, a clinical stage biotechnology company based in Redwood City, CA, is focused on developing immunotherapies for the treatment of cancer, fibrosis, hypercholesterolemia/atherosclerosis and inflammatory diseases. ARMO believes that by harnessing the body's own capability to arm itself against dysregulated cells, it may provide safer and more effective drugs for patients suffering from grievous diseases.
Cytovance Biologics is a biopharmaceutical contract manufacturing company specializing in the production of therapeutic proteins and antibodies from both mammalian cell culture and microbial fermentation. The company also offers process development, cGMP cell banking, and support services from its Oklahoma City facilities.
Source:
Articles in this issue
over 12 years ago
GSK Offers $1 Million Award for Healthcare Innovationsover 12 years ago
Covance MarketPlace Connects Biotech with Potential Partnersover 12 years ago
Pharma Capacity to Produce Cytotoxic Injectable Drugs Constrictsover 12 years ago
Changing Market Dynamics Require New Approaches to Innovationover 12 years ago
Cost Is No Longer the Driving Force for Outsourcingover 12 years ago
Globalization Challenges Drug Regulatorsover 12 years ago
Aesica Pharmaceuticals S.r.I. Implements Serialization Systemover 12 years ago
Frontage Labs Plans Expansion of CMC Facilityover 12 years ago
Novartis Hosts 13th Annual Malaria Expert Panelover 12 years ago
Rentschler Invests in New Stainless-Steel BioreactorsAdvertisement
Related to this article
The FDA approves oral pritelivir for drug-resistant herpes sores in immunocompromised patients; what it means for antiviral development and manufacturing.
This week, drug formulation and manufacturing experts showcased their knowledge, and companies exhibited their products, at CPHI Milan.
FDA approves Teva’s Weltruza, a once-monthly subcutaneous olanzapine for schizophrenia whose copolymer depot eliminates post-injection monitoring.
Equivalence test using two one-sided tests are widely used for demonstrating the comparability of treatment effects in different research fields. The method described in the manuscript aims to use simulations in Microsoft Excel to compute power for 2 one-sided tests for two groups with unequal variances.
Richard Jaenisch examines whether FDA's NAM pathway truly shortens drug pipelines or just shifts the evidentiary burden elsewhere.
Susan J. Schniepp, distinguished fellow with Nelson Labs, and Siegfried Schmitt, PhD, vice president, Technical, with Parexel, clear up some of the confusion about what does and does not need to be complied with regarding standards set by international pharmacopoeias.
Mitigating nitrosamine risk requires assessing each product individually, says Bram Baert, Global Head of Regulatory Affairs at Capsugel, and Sandrine Picco, Senior Analytical Specialist on Capsugel's Innovaform Accelerator Team, in this interview with PharmTech.
Advertisement
Advertisement
Trending on Pharmaceutical Technology
1
Pritelivir Shifts Resistant Herpes Care from Intravenous to Oral
2
Can Continuous Tableting End Scale-Up for Complex Oral Drugs?
3
CPHI Milan: Packaging and Delivery Decisions Must Reflect Real-World Care
4
Manufacturing Intelligence: Organoids, Organ-on-a-Chip, and the Trust Gap
5